See All Slides - tctmd.com

Slides

Presentation TCT 2012

Case Presentation(3)

Presenter: Joachim Schofer

October 22, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

Case Resolution(4)

Presenter: Jie Qian

October 22, 2012

Presentation TCT 2012

AND, Should Also be Based on Hemodynamic Assessments: The Dimensionless AR Index

Presenter: Georg Nickenig

October 22, 2012

Presentation TCT 2012

Clinical Pearls from Experienced Valve-in-Valve Operators: Self-Expanding TAVR for Aortic Valve-in-Valve

Presenter: Jean-Claude Laborde

October 22, 2012

Presentation TCT 2012

Non-Left Main Bifurcation Stenting: Highlights from the Last 12 Months

Presenter: Nick Curzen

October 22, 2012

Presentation TCT 2012

Intravascular Photoacoustics: Progress and Potential for Vulnerable Plaque Imaging

Presenter: Antonius van der Steen

October 22, 2012

Presentation TCT 2012

Taped Case 4: Complex Pelvic Reconstruction: Endovascular Treatment of Benign Prostatic Hypertrophy and Erectile Dysfunction

Presenter: Akaki Archvadze

October 22, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

Presentation TCT 2012

The NOBLE Trial: Novel Aspects and Status Update

Presenter: Leif Thuesen

October 22, 2012

Advertisement

Slides

Case Presentation(3)

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Case Resolution(4)

AND, Should Also be Based on Hemodynamic Assessments: The Dimensionless AR Index

Clinical Pearls from Experienced Valve-in-Valve Operators: Self-Expanding TAVR for Aortic Valve-in-Valve

Non-Left Main Bifurcation Stenting: Highlights from the Last 12 Months

Intravascular Photoacoustics: Progress and Potential for Vulnerable Plaque Imaging

Taped Case 4: Complex Pelvic Reconstruction: Endovascular Treatment of Benign Prostatic Hypertrophy and Erectile Dysfunction

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

The NOBLE Trial: Novel Aspects and Status Update

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content